Related Experiment Video
Updated: Sep 30, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor
Connie L Sivinski1, Karl G Kohlgraf, Michelle L VanLith
1Eppley Institute for Research in Cancer and Allied Diseases and Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-6805, USA.
Abstract:
Previous studies have indicated that different effector cells are required to eliminate MUC1-expressing tumors derived from different organ sites and that different vaccine strategies may be necessary to generate these two different MUC1-specific immune responses. In this study, we characterized molecular components that are required to produce immune responses that eliminate Panc02.MUC1 tumors in vivo by utilizing mice genetically deficient in molecules related to immunity. A parallel study has been reported for a B16.MUC1 tumor model. We confirmed that a CD8(+) effector cell was required to eliminate MUC1-expressing Panc02 tumors, and demonstrated that T cells expressing TCR-alpha/beta and co-stimulation through CD28 and CD40:CD40L interactions played critical roles during the initiation of the anti-Panc02.MUC1 immune response. TCR-alpha/beta(+) cells were required to eliminate Panc02.MUC1 tumors, while TCR-gamma/delta(+) cells played a suppressive non-MUC1-specific role in anti-Panc02 tumor immunity. Type 1 cytokine interferon-gamma (IFN-gamma), but not interleukin-12 (IL-12), was essential for eliminating MUC1-expressing tumors, while neither IL-4 nor IL-10 (type 2 cytokines) were required for tumor rejection. In vitro studies demonstrated that IFN-gamma upregulated MHC class I, but not MHC class II, on Panc02.MUC1 tumor cells. Surprisingly, both perforin and FasL played unique roles during the effector phase of immunity to Panc02.MUC1, while lymphotoxin-alpha, but not TNFR-1, was required for immunity against Panc02.MUC1 tumors. The findings presented here and in parallel studies of B16.MUC1 immunity clearly demonstrate that different effector cells and cytolytic mechanisms are required to eliminate MUC1-expressing tumors derived from different organ sites, and provide insight into the immune components required to eliminate tumors expressing the same antigen but derived from different tissues.
Insights
Immune responses eliminating MUC1-expressing Panc02 tumors require CD8(+) T cells and type 1 cytokine interferon-gamma (IFN-gamma). Different effector cells and mechanisms are needed for MUC1 tumors from distinct origins.
Area of Science:
- Immunology
- Cancer Immunology
- Tumor Microenvironment
Background:
- MUC1 is a tumor-associated antigen expressed in various cancers.
- Eliminating MUC1-expressing tumors may require distinct immune strategies based on tumor origin.
- Previous studies suggest differing immune requirements for MUC1+ tumors from different sites.
Purpose of the Study:
- To characterize the molecular components essential for immune responses against MUC1-expressing Panc02 tumors.
- To elucidate the roles of specific immune cells and cytokines in anti-tumor immunity.
- To compare immune mechanisms for MUC1+ tumors from different tissue origins.
Main Methods:
- Utilized genetically modified mice deficient in specific immune molecules.
- Investigated the role of CD8(+) and T cell receptor (TCR) alpha/beta(+) cells in tumor elimination.
- Assessed the impact of cytokines (IFN-gamma, IL-12, IL-4, IL-10) and effector molecules (perforin, FasL, lymphotoxin-alpha) on tumor rejection.
- Performed in vitro studies to analyze MHC molecule expression on tumor cells.
Main Results:
- CD8(+) effector cells are crucial for eliminating Panc02.MUC1 tumors.
- TCR-alpha/beta(+) T cells and co-stimulation via CD28 and CD40:CD40L are critical for initiating anti-tumor immunity.
- Type 1 cytokine IFN-gamma, but not IL-12, is essential for tumor rejection; type 2 cytokines are not required.
- IFN-gamma upregulates MHC class I on Panc02.MUC1 tumor cells.
- Perforin, FasL, and lymphotoxin-alpha play distinct roles in the effector phase of anti-tumor immunity.
Conclusions:
- Immunity against MUC1-expressing Panc02 tumors relies on TCR-alpha/beta(+) CD8(+) T cells and IFN-gamma.
- Different effector cells and cytolytic mechanisms are necessary for eliminating MUC1+ tumors originating from distinct sites.
- Understanding these distinct immune requirements provides insights for developing targeted cancer vaccines.
Related Concept Videos
01:27Tumor Immunotherapy
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:26Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.